Skip to content

Cannabis: all studies

Page 229 of 288: studies 2,281 to 2,290 of 2,874, newest first. Back to the cannabis overview

Research

The Need for Psychiatric Treatment among Polish Users of Psychoactive Substances Is Increasing: This and Other Results from the Newest PolDrugs Survey

Medicina May 9, 2023 Gniewko Więckiewicz, Julia Marek, Iga Stokłosa et al. 5 citations

Background and Objectives: PolDrugs is the largest Polish naturalistic nationwide survey to present basic demographic and epidemiological data that could potentially prevent harm from illicit substances intake in drugs users. The most recent results were presented in 2021. The goal of this year’s edition was to re-present the above data and compare it to the previous edition’s data to identify...

Psychotogenic potential of prescribed drugs

Australian & New Zealand Journal of Psychiatry May 6, 2023 Julia Lappin, Shane Darke, Michael Farrell

Australian & New Zealand Journal of Psychiatry, 57(6) Interest in prescribing psychoactive drugs as treatments for mental health conditions has been highlighted recently by the decision by the Therapeutic Goods Administration (TGA) to permit, from 1 July 2023, authorised psychiatrists to prescribe medicines containing psilocybin for treatment-resistant depression and...

CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study.

Psychiatry Research May 1, 2023 Kirsten R Müller-vahl, Anna Pisarenko, Natalia Szejko et al. 36 citations

Preliminary data suggest that cannabis-based medicines might be a promising new treatment for patients with Tourette syndrome (TS)/chronic tic disorders (CTD) resulting in an improvement of tics, comorbidities, and quality of life. This randomized, multicenter, placebo-controlled, phase IIIb study aimed to examine efficacy and safety of the cannabis extract nabiximols in adults with TS/CTD (n =...

Trends in drug use among nightclub and festival attendees in New York City, 2017-2022.

International Journal of Drug Policy May 1, 2023 Joseph J Palamar, Austin Le, Charles M Cleland et al. 41 citations

Drug use is prevalent among people who attend electronic dance music (EDM) parties at nightclubs or festivals. This population can serve as a sentinel population to monitor trends in use of party drugs and new psychoactive substances (NPS) that may diffuse through larger segments of the population. We surveyed adults entering randomly selected EDM parties at nightclubs and dance festivals in...

LSD et MDMA en combinaison (Candy Flip)

Psychotropes April 21, 2023 Pierre Poloméni

Les adolescents et jeunes adultes participant à des événements musicaux consomment fréquemment des substances psychoactives pour améliorer la qualité des relations et des perceptions. Parmi ces substances, une association de LSD puis de MDMA, prises à une heure d’intervalle, dénommée Candy Flip, connue depuis longtemps, bénéficie d’une bonne réputation. Notre travail explore ces substances en...

Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: a pilot study.

bioRxiv : the preprint server for biology April 11, 2023 Shinnyi Chou, Kenneth N Fish, David A Lewis et al. preprint

Individuals with schizophrenia are at elevated genetic risks for comorbid cannabis use, and often experience exacerbations of cognitive and psychotic symptoms when exposed to cannabis. These findings have led a number of investigators to examine cannabinoid CB1 receptor (CB1R) alterations in schizophrenia, though with conflicting results. We recently demonstrated the presence of CB1R in both...

Psychedelic Research for Dementia Risks Perpetuating Structural Failures and Inadequacies in Aged Care

AJOB Neuroscience April 3, 2023 Hojjat Soofi, C. Forlini

Carhart-Harris, R., B. Giribaldi, R. Watts, M. Baker-Jones, A. Murphy-Beiner, R. Murphy, J. Martell, A. Blemings, D. Erritzoe, D. J. Nutt, et al. 2021. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine 384 (15):1402–11. doi:10.1056/NEJMoa 2032994. Coulson, A. 2023. Lecanemab approved for use by US FDA. NeuroCentral, 19 Jan. https://www.neuro-central.com/...

Potential Utility of Cannabidiol in Stress-Related Disorders.

Cannabis and Cannabinoid Research April 2023 Nicole A Lookfong, Wesley M Raup-Konsavage, Yuval Silberman

Background: The endocannabinoid (eCB) system plays an important role in homeostatic regulation of anxiety and stress responses; however, the eCB system can be disrupted following traumatic stressors. Additionally, traumatic or chronic stressors that occur during adulthood or early life can cause long-lasting disturbances in the eCB system. These alterations interfere with...

Incidence of Intoxications in the Emergency Department of Galati Hospital with Examples of Cardiovascular Effects of MDMA Intoxication

Diagnostics March 10, 2023 Liliana Dragomir, Virginia Marina, Mihaela Anghele et al.

MDMA (3,4-methylenedioxymethamphetamine; commonly referred to as “Molly” or “ecstasy”) is a synthetic compound, structurally and pharmacologically similar to both amphetamines and mescaline. MDMA differs somewhat from traditional amphetamines in that it is not structurally similar to serotonin. Cocaine is rare and cannabis is consumed less frequently than in Western Europe. Heroin is the drug...

DOI: 10.3390/diagnostics13050940 (opens in new tab) Full text (opens in new tab) Methylen-dioxy-methamphetamine Intoxication Serotonin drug

Psychoactive supplements: What to tell patients

Current Psychiatry March 1, 2023 Marija S. Marković 1 citation

Savvy Psychopharmacology M r.D, age 41, presents to the emergency department (ED) with altered mental status and suspected intoxication.His medical history includes alcohol use disorder and spinal injury.Upon initial examination, he is confused, disorganized, and agitated.He receives IM lorazepam 4 mg to manage his agitation.His laboratory workup includes a negative screening for blood alcohol,...